BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 November 2020 - 8:15AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the compensation committee of BioCryst’s board of directors
granted nine newly-hired employees inducement options to purchase
an aggregate of 163,000 shares of BioCryst common stock on October
30, 2020 as inducements material to each employee entering into
employment with BioCryst. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.82
per share, which is equal to the closing price of BioCryst common
stock on the grant date. The options vest in four equal annual
installments beginning on the one-year anniversary of the grant
date, in each case subject to the new employee’s continued service
with the company. Each stock option has a 10-year term and is
subject to the terms and conditions of BioCryst’s Inducement Equity
Incentive Plan and a stock option agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including ORLADEYO™ (berotralstat), an
oral treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2024 to May 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024